Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy.

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: id:"swepub:oai:DiVA.org:umu-16124" > Conversion towards ...

1 of 1
Previous record
Next record
To hitlist

Details
MARC

Rantapää-Dahlqvist, SolbrittUmeå universitet,Institutionen för folkhälsa och klinisk medicin (author)

Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy.

Article/chapterEnglish2006

Publisher, publication year, extent ...

2009-08-25
Informa UK Limited,2006
printrdacarrier

Numbers

LIBRIS-ID:oai:DiVA.org:umu-16124
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-16124URI
https://doi.org/10.1080/03009740500474578DOI

Supplementary language notes

Language:English
Summary in:English

Part of subdatabase

SwePubSwePub

Classification

Subject category:ref swepub-contenttype
Subject category:art swepub-publicationtype

Notes

OBJECTIVES: To analyse the effects of infliximab infusions on serum levels of lipids in patients with rheumatoid arthritis (RA) treated for 2 years. METHODS: Fifty-two patients (41 females and 11 males) with RA undergoing infliximab treatment (3 mg/kg) were consecutively recruited into the study. The mean (+/-SD) age of the patients was 54.6+/-12.5 years and mean disease duration was 14.1+/-8.6 years. Blood was sampled before infusion at baseline, and at 3, 6, 12, 18 and 24 months. Forty-one of the patients were also treated with methotrexate, 13 with other disease-modifying anti-rheumatic drugs (DMARDs) and 28 with prednisolone (<10 mg daily). For comparison, lipid levels were followed for 2 years in 70 consecutively included patients with early RA during treatment with conventional DMARDs. RESULTS: There was an initial increase in plasma levels of cholesterol, high density lipoprotein (HDL)-cholesterol, low density lipoprotein (LDL)-cholesterol, and LDL/HDL and total/HDL cholesterol ratios. However, after 3 months HDL-cholesterol decreased significantly, followed after 6 months by cholesterol and LDL-cholesterol. The LDL/HDL and total/HDL-cholesterol ratios remained significantly raised. HDL-cholesterol increased and the ratios improved in patients with early RA receiving conventional treatment. The changes over time differed significantly between the patient groups. CONCLUSION: During infliximab infusion a pro-atherogenic lipid profile developed despite reduced inflammatory activity. The long-term decrease in HDL-cholesterol was unexpected considering the known effects of tumour necrosis factor-alpha (TNFalpha).

Added entries (persons, corporate bodies, meetings, titles ...)

Engstrand, S (author)
Berglin, EvaUmeå universitet,Institutionen för folkhälsa och klinisk medicin(Swepub:umu)evbe0009 (author)
Johnson, OweUmeå universitet,Institutionen för folkhälsa och klinisk medicin(Swepub:umu)ovjo0001 (author)
Umeå universitetInstitutionen för folkhälsa och klinisk medicin (creator_code:org_t)

Related titles

In:Scand J Rheumatol: Informa UK Limited35:2, s. 107-11
In:Scandinavian Journal of Rheumatology: Informa UK Limited35:2, s. 107-110300-97421502-7732

Internet link

Find in a library

Scand J Rheumatol (Search for host publication in LIBRIS)

To the university's database

1 of 1
Previous record
Next record
To hitlist

Find more in SwePub

By the author/editor: Rantapää-Dahlqvi ...; Engstrand, S; Berglin, Eva; Johnson, Owe

Articles in the publication: Scand J Rheumato ...; Scandinavian Jou ...

By the university: Umeå University

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se